



US005116863A

United States Patent [19][11] **Patent Number:** **5,116,863****Oshima et al.**[45] **Date of Patent:** **May 26, 1992**

- [54] **DIBENZ[B,E]OXEPIN DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS THEREOF**
- | | | | |
|-----------|---------|----------------|---------|
| 4,465,835 | 8/1984 | Takizawa | 546/133 |
| 4,585,788 | 4/1986 | Helsley et al. | 549/354 |
| 4,596,804 | 6/1986 | Takizawa | 514/253 |
| 4,871,865 | 10/1989 | Lever et al. | 549/354 |
| 4,923,892 | 5/1990 | Lever et al. | 514/450 |

- [75] **Inventors:** Etsuo Oshima; Toshiaki Kumazawa; Shizuo Otaki; Hiroyuki Obase, all of Shizuoka; Kenji Ohmori, Mishima; Hidee Ishii, Shizuoka; Haruhiko Manabe, Shizuoka; Tadafumi Tamura, Shizuoka; Katsuichi Shuto, Shizuoka, all of Japan

FOREIGN PATENT DOCUMENTS

- | | | |
|---------|---------|--------------------|
| 0069810 | 1/1983 | European Pat. Off. |
| 0085870 | 8/1983 | European Pat. Off. |
| 0130555 | 1/1985 | European Pat. Off. |
| 214779 | 3/1987 | European Pat. Off. |
| 0021679 | 2/1983 | Japan |
| 0227879 | 12/1984 | Japan |
| 1003950 | 9/1965 | United Kingdom |
| 1018995 | 2/1966 | United Kingdom |

- [73] **Assignee:** Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan

[21] **Appl. No.:** 20,900[22] **Filed:** Mar. 2, 1987[30] **Foreign Application Priority Data**

Mar. 3, 1986 [JP] Japan 61-45676

[51] **Int. Cl.⁵** A61K 31/335; C07D 313/12[52] **U.S. Cl.** 514/450; 548/215;

548/525; 549/354; 514/212; 514/228.2;

514/232.8; 514/253; 514/320; 514/374;

514/422; 540/596; 540/600; 544/62; 544/137;

544/147; 544/369; 544/375; 544/58.7; 546/196

[58] **Field of Search** 540/596, 602; 544/62,

544/137, 147, 369, 375, 98.7; 546/196; 548/215,

525; 549/354; 514/212, 222, 233, 234, 236, 237,

253, 320, 374, 422, 450, 228.2, 232.8

[56] **References Cited****U.S. PATENT DOCUMENTS**

- | | | | |
|-----------|---------|---------------|-----------|
| 3,354,155 | 11/1967 | Tretter | 549/354 X |
| 3,420,851 | 1/1969 | Bloom et al. | 549/354 |
| 3,509,176 | 4/1970 | Winter et al. | 260/333 |
| 4,282,365 | 8/1981 | Rokach | 548/252 |
| 4,396,550 | 8/1983 | Takizawa | 549/354 |

OTHER PUBLICATIONS

Wellcome Foundation Ltd., Chemical Abstracts, vol. 107 (1987) 58,673r.

Metvosova, *Arz.-Forsch.*, vol. 13 (1963) 1039:43.Benesova, *Arz.-Forsch.*, vol. 14 (1964) 100:3.*Chem. Abs.*, vol. 63 (1965) 16366a.*Drugs*, vol. 13 (1977) 161:218.*J. Med. Chem.*, vol. 19, No. 7 (1976) 941:6.*J. Med. Chem.*, vol. 20, No. 11 (1977) 1499:501.*J. Med. Chem.*, vol. 21, No. 7 (1978) 633:9.*Primary Examiner*—Richard L. Raymond*Attorney, Agent, or Firm*—Fitzpatrick, Cella, Harper & Scinto[57] **ABSTRACT**

Novel dibenz[b,e]oxepin derivatives are employed in the treatment and control of allergic conditions such as allergic asthma and also employed in the treatment of inflammation.

3 Claims, No Drawings

1

DIBENZ[B,E]OXEPIN DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS THEREOF

BACKGROUND OF THE INVENTION


Heretofore, it has been known that 11-unsubstituted, 11-hydroxy or 11-oxodibenz[b,e]oxepin derivative is used for antiinflammatory agents [J. Med. Chem., 21, 633-639 (1978)].

Further, it is known that dibenz[b,e]oxepin derivative wherein substituents Ra and Rb at 11-position have the following definitions, is employed in the treatment and control of allergic conditions (U.S. Pat. No. 4,282,365). Ra: H, OH, lower alkoxy, lower alkylthio, lower alkylsulfanyl, lower alkylsulfonyl, arylthio, NH₂, NHCHO or imidazolyl;

Rb: H or lower alkyl; or Ra and Rb taken together are =O, =CH—Rc wherein Rc is H or aryl.


Furthermore, it is known that 11-(4-methylpiperazino) dibenz[b,e]oxepin derivative has an antiasthmatic activity (U.S. Pat. No. 4,396,550, U.S. Pat. No. 4,465,835, EP-A-38564).

It is also known that dibenz[b,e]oxepin derivative having the following formula:




wherein Rd and Re are lower alkyl and Rf is lower alkyl or halogen, has an antiasthmatic activity (EP-A-85870).

Dibenz[b,e]oxepin derivative having an antiallergic activity and having the following structural formula:



wherein Rg and Rh are alkyl, r is 2 or 3 and Ri is alkyl or halogen is known (JP-A-227879/84).


Dibenz[b,e]oxepin derivative having an antiallergic activity and having the following structural




wherein Rj is 4-alkylpiperazino, 3-quinuclidylamino or —X_a—(CH₂)_{hd} s—NR_l/R_m wherein X_a is —NH—, —S— or —O—, s is 2 or 3 and R_l and R_m are alkyl, and R_k is CN, 5-tetrazolyl, CONH₂ or CO₂R_n wherein R_n is H, alkyl or 1-(ethoxycarbonyloxy)ethyl is known (EP-A-130555).

2

Doxepin having an antidepressant activity and having the following structural formula is known [Drugs, 13, 161 (1977)].



Dothiepin having an antidepressant activity and having the following structural formula is known [Arz.-Forsch., 13 1039 (1963); *ibid.*, 14 100 (1964)].




As the compound having both an antiallergic activity and an antiinflammatory activity, steroids are known.

It is always desired that a novel compound having an antiallergic activity or an antiinflammatory activity be developed.

SUMMARY OF THE INVENTION

The present invention relates to a dibenz[b,e]oxepin derivative represented by the formula (I):



Wherein A represents a hydroxymethyl, a lower alkoxy-methyl, a triphenylmethyloxymethyl, a lower alkanoyloxymethyl, a lower alkanoyl, a carboxy, a lower alkoxy carbonyl, a triphenylmethyloxycarbonyl, —CONR₁R₂ (wherein R₁ and R₂ are the same or different and represent hydrogen atom or lower alkyl) 4,4-dimethyl-2-oxazoline-2-yl group or —CONHOH; Y represents —(CH₂)_m—, —CHR₃—(CH₂)_m— or —CR₄=CR₅—(CH₂)_{hd} m— which is substituent at 2— or 3-position of the mother nucleus (wherein R₃ represents a lower alkyl, R₄ and R₅ are the same or different and represent a hydrogen atom or a lower alkyl, m is 0, 1, 2, 3 or 4, and the left side of the group of Y mentioned above is bound to benzen nucleus); X represents =N—, =CH— or —CH₂—; n is 0, 1, 2, 3 or 4; Z represents 4-methylpiperazino, 4-methylhomopiperazino, piperidino, pyrrolidino, thiomorpholino, morpholino, or —NR₆R₇ (wherein R₆ and R₇ are the same or different and represent a hydrogen atom or a lower alkyl); and — means a single bond or double bond [hereinafter referred to as Compound (I) and Compounds with other formula numbers are hereinafter likewise referred to], and a pharmaceutically acceptable salt thereof. The present invention further pertains to a pharmaceutical

composition containing an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient, and a carrier or an excipient.

The present Compound (I) is useful for treatment of allergic conditions and inflammation.

DETAILED DESCRIPTION OF THE INVENTION

In the definition of each group of formula (I), the lower alkyl group includes straight or branched chain alkyl groups having 1 to 6 carbon atoms, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, etc. In the definition of the group A, lower alkyl moiety of lower alkoxyethyl group and lower alkoxyethyl group has the same meaning as previously defined.

The lower alkoxyethyl group includes methoxymethyl, ethoxymethyl, n-propoxymethyl, isopropoxy, etc. and the lower alkoxyethyl group includes methoxycarbonyl, ethoxycarbonyl, etc.


In the definition of the group A, the lower alkyl moiety of lower alkanoyl group and lower alkanoyloxymethyl group has the same meaning as previously defined.

The lower alkanoyl group includes formyl, acetyl, etc. and the lower alkanoyloxymethyl group includes formyloxymethyl, acetyloxymethyl, etc.


The pharmaceutically acceptable salt of Compound (I) includes pharmaceutically acceptable acid addition salt, metal salt, ammonium salt, organic amine addition salt, amino acid addition salt, etc.

The pharmaceutically acceptable acid addition salt of Compound (I) includes inorganic acid salts such as hydrochloride, sulfate, phosphate, etc., and organic acid salts such as acetate, maleate, fumarate, tartrate, citrate, etc. The pharmaceutically acceptable metal salt includes alkali metal salts such as sodium salt, potassium salt, etc., alkaline earth metal salts such as magnesium salt, calcium salt, etc., and aluminium salt, zinc salt, etc. The pharmaceutically acceptable organic amine addition salt includes addition salt of morpholine and piperidine and the pharmaceutically acceptable amino acid addition salt includes addition salt of lysine, glycine, phenylalanine, etc.

Compound (I) is prepared by using a compound represented by the formula (II):



wherein Y and A have the same meanings as previously defined or a compound represented by the formula (III):



wherein Y and A have the same meanings as previously defined as the starting compound. Compound (II) is

disclosed in J. Med. Chem., 19, 941 (1976), *ibid.*, 20, 1499 (1977) and JP-A-21679/83.



Compound (III) wherein $-Y-A$ is $-COOH$ is disclosed in JP-A-21679/83 and the other Compounds (III) can be prepared according to the method described in the publication though they do not occur in the publication.

The process for preparing Compound (I) is explained, depending on the kind of the group X.

Process A

Synthesis of Compound (I) wherein X is $=CH-$ (Part 1)

The carboxy group of Compound (IIa) is protected according to the following reaction scheme.




In the formulae, Y has the same meaning as previously defined, and Compound (IIa) is included in Compound (II) (compounds with an alphabet suffix following formula number are likewise included in compounds with common formula No.).

Compound (IIa) is reacted with 1 to 5 equivalents of thionyl chloride and 1 to 5 equivalents of 2-amino-2-methyl-1-propanol on the basis of Compound (IIa) in an inert solvent such as methylene chloride, if necessary in the presence of a base such as triethylamine at a temperature of from 0° C. to room temperature for 1-24 hours to form Compound (IV). Compound (IV) can also be obtained by reacting Compound (IIa) with thionyl chloride in advance and then with 2-amino-2-methyl-1-propanol.

Compound (IV) is reacted with 1-5 equivalents of thionyl chloride in an inert solvent such as methylene chloride, toluene and benzene at a temperature of from 0° C. to room temperature for 1-24 hours to form Compound (V).

Compounds (Ia) and (Ib) can be prepared from Compound (V) according to the following reaction scheme.



In the formulae, Y, Z, and n have the same meanings as previously defined. R_8 is hydrogen or a lower alkyl group, R_8' is a lower alkyl group and Hal is halogen.

As used herein, the term lower alkyl has the same meaning as that of lower alkyl in each group of formula (I). Halogen includes chlorine, bromine and iodine. Compound (V) is reacted with 1-5 equivalents of Compound (VI) in an inert solvent such as tetrahydrofuran and diethyl ether under atmosphere of an inert gas such as nitrogen and argon to form Compound (VII). The reaction is carried out at a temperature of from 0° C. to room temperature and is usually completed in 1-24 hours.

Compound (VII) is reacted with 1-5 equivalents of thionyl chloride or phosphoryl chloride in an inert solvent such as methylene chloride in the presence of a base such as pyridine to form Compound (Ia). The reaction is carried out at a temperature of from 0° C. to room temperature and is completed in 1-24 hours.

Compound (Ia) is incubated in an alcohol containing water, such as aqueous methanol solution, in the pres-


ence of an appropriate acidic catalyst such as p-toluenesulfonic acid at a temperature of from room temperature to the boiling point of the solvent to form Compound (Ib) wherein R_8 is H. The reaction is completed in 1-24 hours.

Compound (VII) is incubated in an alcohol of R_8' OH in the presence of an appropriate acidic catalyst such as p-toluenesulfonic acid at a temperature of from room temperature to the boiling point of the solvent to form Compound (Ib) wherein R_8 is a lower alkyl. The reaction is completed in 1-24 hours.


Process B

Synthesis of Compound (I) wherein X is =CH— (Part 2)

The carboxy group of a compound represented by the formula (IIa) can be converted to a lower alkoxymethyl group or a trityloxymethyl group according to the following reaction scheme.



-continued



In the formulae, Y has the same meaning as previously defined, R_9 is a lower alkyl group and R_9' is a trityl group or a lower alkyl group. The term lower alkyl has the same meaning as that of lower alkyl in each group in formula (I).

Compound (IIa) is reduced with 1-5 equivalents of lithium aluminium hydride in tetrahydrofuran at a temperature of from 0° C. to room temperature for 1-24 hours to form Compound (VIII).

Compound (VIII) is reacted with 1-5 equivalents of trityl chloride in pyridine at a temperature of from room temperature to 100° C. for 1-24 hours to form Compound (IX).

Compound (IX) is oxidized with 1-5 equivalents of an appropriate oxidizing agent such as potassium permanganate and pyridinium chlorochromate in an inert solvent such as methylene chloride and acetone to form Compound (XI) wherein R_9' is trityl. The reaction is


35

carried out at a temperature of from 0° C. to the boiling point of the solvent and is completed in 1-24 hours.

Compound (VIII) is incubated in an alcohol of R_9OH in the presence of an appropriate acidic catalyst such as sulfuric acid at a temperature of from room temperature to the boiling point of the solvent to form Compound (X). The reaction is usually completed in 1-24 hours.

Compound (X) is oxidized with 1-5 equivalents of an appropriate oxidizing agent such as Jones reagent in an inert solvent such as acetone to form Compound (XI) wherein R_9' is a lower alkyl. The reaction is carried out at a temperature of from 0° C. to the boiling point of the solvent and is usually completed in 1-24 hours.

The compounds represented by the formulae (Ic) and (Id) and if desired, the compound represented by the formula (Ie) can be synthesized from Compound (XI) according to the following reaction scheme.



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.